ERAS Key Statistics, Chart & Performance
The current stock price of ERAS is 3.64 USD. In the past month the price increased by 27.27%. In the past year, price increased by 43.31%.
ERAS Latest News, Press Relases and Analysis
ERAS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.44B | ||
| AMGN | AMGEN INC | 14.91 | 175.55B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.89 | 114.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.66 | 78.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 768.82 | 51.80B | ||
| INSM | INSMED INC | N/A | 42.33B | ||
| NTRA | NATERA INC | N/A | 31.12B | ||
| BIIB | BIOGEN INC | 10.28 | 25.25B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.36 | 22.00B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B | ||
| INCY | INCYTE CORP | 15.21 | 19.17B |
Related stock screener links
About ERAS
Company Profile
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Company Info
ERASCA INC
3115 Merryfield Row, Third Floor
San Diego CALIFORNIA US
Employees: 103
Phone: 18584656511
ERASCA INC / ERAS FAQ
Can you describe the business of ERASCA INC?
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Can you provide the latest stock price for ERASCA INC?
The current stock price of ERAS is 3.64 USD. The price increased by 3.41% in the last trading session.
Does ERAS stock pay dividends?
ERAS does not pay a dividend.
What is the ChartMill rating of ERASCA INC stock?
ERAS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ERAS stock listed?
ERAS stock is listed on the Nasdaq exchange.
How many employees does ERASCA INC have?
ERASCA INC (ERAS) currently has 103 employees.
Who owns ERASCA INC?
You can find the ownership structure of ERASCA INC (ERAS) on the Ownership tab.
ERAS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ERAS. When comparing the yearly performance of all stocks, ERAS is one of the better performing stocks in the market, outperforming 95.61% of all stocks.
ERAS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ERAS. No worries on liquidiy or solvency for ERAS as it has an excellent financial health rating, but there are worries on the profitability.
ERAS Financial Highlights
Over the last trailing twelve months ERAS reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 45.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.37% | ||
| ROE | -36.7% | ||
| Debt/Equity | 0 |
ERAS Forecast & Estimates
16 analysts have analysed ERAS and the average price target is 4.87 USD. This implies a price increase of 33.88% is expected in the next year compared to the current price of 3.64.